Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yigla, M.
Right arrow Articles by Reisner, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yigla, M.
Right arrow Articles by Reisner, S. A.
(Chest. 2003;123:1577-1582.)
© 2003 American College of Chest Physicians

Pulmonary Hypertension in Patients With End-Stage Renal Disease*

Mordechai Yigla, MD; Farid Nakhoul, MD; Anat Sabag, MD; Naveh Tov, MD; Bella Gorevich, MD; Ziad Abassi, PhD and Shimon A. Reisner, MD

* From the Departments of Nephrology (Drs. Nakhoul and Gorevich) and Cardiology (Dr. Reisner), Division of Pulmonary Medicine (Drs. Yigla, Sabag and Tov), Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa; and Nephrology Research Laboratory (Dr. Abassi), Technion-Israel Institute of Technology, Haifa, Israel.

Correspondence to: Mordechai Yigla, MD, Division of Pulmonary Medicine, Rambam Medical Center, PO Box 9602, Haifa 31096, Israel; e-mail: m_yigla{at}rambam.health.gov.il

Background: The aims of this study were to evaluate the incidence of unexplained pulmonary hypertension (PH) among patients with end-stage renal disease (ESRD) and to suggest possible etiologic factors.

Methods: The incidence of PH was prospectively estimated by Doppler echocardiography in 58 patients with ESRD receiving long-term hemodialysis via arteriovenous access, and in control groups of 5 patients receiving peritoneal dialysis (PD) and 12 predialysis patients without a known other cause to suggest the presence of PH. Clinical variables were compared between patients with and without PH receiving hemodialysis. Changes in pulmonary artery pressure (PAP) values before and after onset of hemodialysis via arteriovenous access, arteriovenous access compression, and successful kidney transplantation were recorded.

Results: PH > 35 mm Hg was found in 39.7% of patients receiving hemodialysis (mean ± SD, 44 ± 7 mm Hg; range, 37 to 65 mm Hg), in none of the patients receiving PD, and in 1 of 12 predialysis patients. Patients with PH receiving hemodialysis had a significantly higher cardiac output (6.9 L/min vs 5.5 L/min, p = 0.017). PH developed in four of six patients with normal PAP after onset of hemodialysis therapy via arteriovenous access. One-minute arteriovenous access compression in four patients decreased the mean systolic PAP from 52 ± 7 to 41 ± 4 mm Hg (p = 0.024). PH normalized in four of five patients receiving hemodialysis following kidney transplantation. Kaplan-Meier survival analysis according to PAP values revealed significant survival differences (p < 0.024).

Conclusions: This study demonstrates a surprisingly high incidence of PH among patients with ESRD receiving long-term hemodialysis with surgical arteriovenous access. Both ESRD and long-term hemodialysis via arteriovenous access may be involved in the pathogenesis of PH by affecting pulmonary vascular resistance and cardiac output.

Key Words: arteriovenous access • end-stage renal disease • hemodialysis • pulmonary hypertension




This article has been cited by other articles:


Home page
ChestHome page
H. A. Faraz, M. K. Shah, T. A. Qureshi, and K. K. Mubarak
PULMONARY HYPERTENSION IN END-STAGE RENAL DISEASE: CLINICAL AND HEMODYNAMIC IMPROVEMENT WITH ENDOTHELIN RECEPTOR ANTAGOIST BOSENTAN
Chest Meeting Abstracts, October 1, 2006; 130(4): 304S - 305S.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. Shlomi, D. Shitrit, D. Bendayan, G. Sahar, M. Saute, and M. R. Kramer
Two Successful Lung Transplantations From a Dialysis-Dependent Donor.
Ann. Thorac. Surg., March 1, 2006; 81(3): 1131 - 1132.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C.-F. Lam, T. E. Peterson, A. J. Croatt, K. A. Nath, and Z. S. Katusic
Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2334 - H2341.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.